Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED)‘s stock had its “hold” rating reaffirmed by stock analysts at BMO Capital Markets in a report issued on Thursday.

Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 4.11% during mid-day trading on Thursday, hitting $20.437. The stock had a trading volume of 203,182 shares. Oncomed Pharmaceuticals has a 52 week low of $12.07 and a 52 week high of $42.34. The stock’s 50-day moving average is $20.66 and its 200-day moving average is $26.05. The company’s market cap is $608.2 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. Analysts expect that Oncomed Pharmaceuticals will post $-1.35 EPS for the current fiscal year.

In other Oncomed Pharmaceuticals news, Insider Austin Gurney sold 4,000 shares of the company’s stock on the open market in a transaction dated Friday, August 22nd. The stock was sold at an average price of $20.00, for a total value of $80,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

OMED has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. Oncomed Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $37.00.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.